Cargando…
One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease
Aim: Paclitaxel-eluting stents' (Eluvia and Zilver PTX) effectiveness has been recently reported for femoropopliteeal (FP) lesions. However, there is no evaluation of one-year late lumen loss (LLL). Therefore, we evaluated one-year LLL after implantation with Eluvia or Zilver PTX. Methods: This...
Autores principales: | Soga, Yoshimitsu, Fujihara, Masahiko, Tomoi, Yusuke, Iida, Osamu, Ishihara, Takayuki, Kawasaki, Daizo, Ando, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049471/ https://www.ncbi.nlm.nih.gov/pubmed/31257301 http://dx.doi.org/10.5551/jat.50369 |
Ejemplares similares
-
24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent
por: Iida, Osamu, et al.
Publicado: (2021) -
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
por: Dake, Michael D., et al.
Publicado: (2016) -
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results
por: Kichikawa, Kimihiko, et al.
Publicado: (2018) -
Mortality risk of femoropopliteal paclitaxel-coated devices remains inconclusive
por: Takahara, Mitsuyoshi, et al.
Publicado: (2019) -
Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease
por: Müller-Hülsbeck, Stefan, et al.
Publicado: (2016)